Aims/hypothesis Mitochondrial respiration has been linked to insulin resistance. We studied mitochondrial respiratory capacity and substrate sensitivity in patients with type 2 diabetes (patients), and obese and lean control participants. 
Introduction
Insulin resistance is a hallmark of type 2 diabetes and presents itself primarily in skeletal muscle and liver, both of which are highly metabolically active tissues. The mechanisms underlying insulin resistance have not yet been fully elucidated, but skeletal muscle mitochondrial dysfunction has been linked to insulin resistance and type 2 diabetes. Studies have suggested that low mitochondrial content [1, 2] , decreased respiratory capacity per mitochondrion [3] and increased oxidative stress due to increased mitochondrial production of reactive oxygen species (ROS) or a reduced antioxidant defence system or both [4] [5] [6] may induce or contribute to skeletal muscle insulin resistance in patients with type 2 diabetes. However, the issue is controversial and several studies have concluded that mitochondrial respiration is not associated with insulin resistance [7] [8] [9] [10] [11] [12] [13] , when respiratory capacity is expressed relative to mitochondrial content (i.e. intrinsic mitochondrial function), as estimated for example by citrate synthase activity or mitochondrial DNA (mtDNA).
Mitochondrial respiration ex vivo is usually measured in permeabilised fibres or in isolated mitochondria by stimulating respiration by provision of substrates in saturating concentrations to achieve maximal coupled or uncoupled respiration [7, 8] . However, this may not always be the best approach, as recent animal and cell culture studies have shown that substrate overload alters mitochondrial substrate handling and substrate oxidation in insulin-resistant models. It was proposed that this abnormality may induce or at least contribute to insulin resistance [14] .
In a previous study, mitochondrial half maximal substrate concentration (C 50 ) and maximal respiration (V Á max ) were determined in biopsies from the right auricula of the heart from patients with and without type 2 diabetes. C 50 did not differ between groups, but V Á max was significantly reduced in patients with type 2 diabetes [15] . However, right auricula heart tissue is probably not representative of metabolic characteristics of insulin-resistant skeletal muscle, so the generalisability of these data to diabetic muscle at large is probably limited.
With the present study, we have now determined the substrate sensitivity of the mitochondrial complexes I and II, and studied classical Michaelis-Menten kinetics in human skeletal muscle samples from patients with type 2 diabetes, and from two glucose-tolerant healthy control groups, one obese, the other lean. Substrate sensitivity measured in permeabilised fibres integrates the entire cascade of events leading to generation of ATP in the mitochondria. It represents transport of substrate and enzyme activity in the citric cycle, which lead to generation of NADH and FADH 2 , both of which are transferred to complex I and complex II in the electron transport chain for ATP production. We also determined fibre type composition in the muscle biopsies, because studies in rats have shown differences in MichaelisMenten kinetic variables [16] and in ROS production between fibre types [17] .
Thus, the aim of our study was to investigate mitochondrial substrate handling by measuring V Á max and the sensitivity (C 50 ) of mitochondrial respiration in skeletal muscle. This was done using three different substrates providing electrons for complex I (glutamate), complex II (succinate) and complex I+II (octanoyl-carnitine). We hypothesised that the maximal respiratory capacity would not differ between the groups, but that the sensitivity of the complexes would be decreased in patients with type 2 diabetes.
Methods
Participants We included 12 men with type 2 diabetes, ten age-and BMI-matched obese male controls and ten agematched lean male controls in this study (Table 1) . Patients with type 2 diabetes were being treated with metformin (1,000-2,000 mg; n=8), glimepiride (4-8 mg; n=4) or insulin (400 units; n=1), with one patient being treated by diet. Other medications included hydroxy-3-methylglutarylcoenzyme A reductase inhibitors (simvastatin 20-40 mg; n=8) and ACE inhibitors (10-20 mg; n=8). To maintain optimal glycaemic and cardiovascular control, we deliberately chose not to discontinue any medication (i.e. induce a 'wash-out period'). Both control groups had normal glucose tolerance (fasting glucose <6.0 mmol/l; HbA 1c <6.0%) and were not taking any medication. None of the participants had signs or a history of ischaemic heart disease and all were able to complete a bicycle test to measure maximal oxygen uptake (V Á O 2max Þ without adverse reactions. Participants were instructed to abstain from alcohol and strenuous exercise the day before each experiment. Lean control participants were characterised by lower body weight, BMI, body fat per cent and fasting plasma insulin concentrations than patients and obese control participants (Table 1) . V Á O 2max was higher in lean control participants (Table 1) . Lean control participants were more physically active than the other groups, but none of them performed endurance training. Participants were examined on two separate days after an overnight (10 h) fast. ) clamp was performed [18] . During the final 20 min of the clamp ventilated hood measurements were repeated.
The Ethics Committee of the Municipality of Copenhagen and Frederiksberg, Denmark, approved (file number H-KF-320893) the study protocol, and oral and written consent were obtained from each participant in accordance with the Helsinki Declaration.
Analytical procedures
The biopsy was divided into two parts. One was prepared for respirometric measurements [7] . The other was snap-frozen in liquid nitrogen within 15 s of sampling and stored at −80°C until further analysis.
Citrate synthase and β-hydroxy-acyl-CoA-dehydrogenase (HAD) activities were measured as previously described [19] , with one minor change consisting of use of a TissueLyser II (Qiagen, Hilden, Germany) to make the homogenate. The homogenates for citrate synthase and HAD analysis were also used for Western blots. From each sample 15 μg total protein was separated by SDS-PAGE on 12.5% gels (Criterion; Bio-Rad, Hercules, CA, USA) and electrophoretically transferred to polyvinylidene difluoride membranes in a tank buffer system (transfer buffer: 25 mmol/l Tris, 192 mmol/l glycine and 20% methanol [wt/vol.]). Membranes were probed with antibodies against subunits for each of the five complexes in the mitochondrial oxidative phosphorylation system: (1) complex I (the 20 kDa subunit encoded by NDUFB8); (2) complex II (30 kDa subunit); (3) complex III (the 43 kDa core protein 2 subunit); (4) complex IV (22 kDa subunit II); and (5) complex V (the 55 kDa subunit α). All of the above antibodies were mixed using a kit (Human Total OXPHOS Human WB Antibody Cocktail; MitoSciences, Eugene, Oregon, USA). Antibodies against manganese superoxide dismutase (MnSOD; anti-MnSOD; Millipore, Billerica, MA, USA) were also used. Membranes were then incubated with horseradish-peroxidase-labelled secondary antibody (Dako, Glostrup, Denmark). The antigen-antibody complexes were visualised by electrochemiluminescence using a charge-coupled-device-based system (LAS-3000 Luminescent Image Analyser; Fujifilm, Tokyo, Japan) and quantified using a software package (Multi Gauge version 3.0; Fujifilm). A control homogenate was included twice on each gel. All samples were measured relative to the mean value of the control sample for each specific band. Citrate synthase and HAD homogenates were used to quantify the myosin heavy chain (MHC) composition of the muscle by SDS-PAGE [20] . Quantification of genomic and mtDNA content was performed as previously described [21] . Blood samples were collected in chilled tubes and immediately centrifuged for 10 min (2,500 g; 4°C). The plasma fraction was collected and stored at −20°C or −80°C prior to analysis. Plasma glucose concentrations during the clamp were measured on an automated glucose analyser (ABL800-flex; Radiometer, Copenhagen, Denmark). HbA 1c was analysed using a device (DCA2000+; Bayer Healthcare, Elkhart, IN, USA) based on the latex immunoagglutination inhibition method. Plasma insulin concentrations were determined using an ELISA kit (Dako). Plasma NEFA concentration was measured using a kit (NEFA-C test; Wako Chemical, Neuss, Germany). Concentrations of glycerol, triacylglycerol, cholesterol, HDL and LDL were measured on an automated analyser (Hitachi 912; Roche, Mannheim, Germany) using standard applications.
Mitochondrial respiration protocols Muscle samples were gently dissected on ice using sharp forceps and a magnifying glass, and permeabilised in a relaxing solution with saponin (50 μg/ml) for 30 min, followed by rinsing twice for 10 min in mitochondrial respiration medium [7] . Muscle fibres were carefully weighed and added to the respirometer.
Three substrate and inhibitor protocols (Protocol-1, -2, -3) were employed in duplicate. In Protocol-1, state 2 respiration was assessed with malate (M, 2 mmol/l), followed by state 3 respiration(M 3 , 5 mmol/l, ADP). Subsequently, glutamate (GM 3 , complex I substrate) was titrated in 11 steps (0.1-96.0 mmol/l), followed by cytochrome c (10 μmol/l) to control for outer mitochondrial membrane integrity. Finally rotenone (0.5 μmol/l) was added to inhibit 
(50) (25) (100) complex I. In Protocol-2, state 2 respiration was assessed with malate (M, 2 mmol/l), followed by state 3 respiration (M 3 , 5 mmol/l, ADP). Glutamate (GM 3 , 10 mmol/l) (complex I substrate) was added and succinate (GMS 3 , complex II substrate) was titrated in ten steps (0.1-48.0 mmol/l), followed by cytochrome c (10 μmol/l) and malonate (5 mmol/l) in order to inhibit complex II. Finally rotenone (0.5 μmol/l) was added to inhibit complex I. Finally, in Protocol-3, state 2 respiration was assessed with malate (M, 2 mmol/l) followed by state 3 respiration (M 3 , 5 mmol/l, ADP), followed by addition of octanoylcarnitine (MO 3 , providing electrons for complex I and II) titrated in ten steps (5-2,000 μmol/l). Last, cytochrome c (10 μmol/l) was added. Representative traces from the protocols are shown in Fig. 1 . C 50 was determined in isolated mitochondria from four lean control participants to study possible differences from results generated using the permeabilised fibres. Protocol-1 and -2 were used for this purpose. Isolation of mitochondria from skeletal muscle has been described in detail elsewhere [22] .
Calculations Glucose clearance was calculated as the glucose infusion rate divided by glucose concentration. Standard equations were used for indirect calorimetric calculations [23] . To determine C 50 and V Á max , a non-linear regression (one site saturation equation) in SigmaPlot 11.0 (Systat Software, San Jose, CA, USA) was used based on the individual raw data from the recordings of respiratory fluxes.
Statistics Data are presented as means ± SE. A p value of p<0.05 was considered significant. One-and two-way ANOVAs with repeated measures for the time factor were performed. Significant main effects or interactions were analysed by the Holm-Sidak post hoc test. If the normality test failed, data were log 10 transformed and reanalysed. All statistical analysis was performed in SigmaStat 3.1 (Systat Software).
Results
Plasma insulin concentrations during the clamp were similar between patients with type 2 diabetes (396±46 pmol/l [means ± SE]), and obese (391±20 pmol/l) and lean control participants (407±11 pmol/l). Insulin sensitivity differed significantly (p<0.05) between the groups (patients with type 2 diabetes <obese controls<lean controls; Fig. 2 ). At baseline, the whole-body respiratory exchange ratio was 0.88±0.01, 0.83±0.02 and 0.85±0.02 (means ± SE) in patients with type 2 diabetes and obese and lean control participants, respectively (p>0.05). With hyperinsulinaemia, the respiratory exchange ratio increased (p<0.05) in patients with type 2 diabetes, and in obese and lean controls (to 0.92±0.01, 0.89±0.02 and 0.92±0.02 [means ± SE], respectively) with no difference between the magnitude of increase.
Skeletal muscle from patients with type 2 diabetes was characterised by less (p<0.05) MHC I content than in the other groups, in whom MHC I was >50% (Table 2 ). In accordance with the higher V Á O 2max in lean control participants, the proportion of MHC IIX was very low in this group and significantly (p<0.05) lower than in patients with type 2 diabetes, with a tendency toward a lower proportion (p=0.069) than in obese control participants ( Table 2) . Citrate synthase and HAD activities were similar between patients with type 2 diabetes and obese control participants, but higher activities (p<0.05) were seen in lean controls. This is supported by the fact that the amount of mtDNA copies also tended (p=0.065) to be higher in lean control participants (Table 2) , and also by the higher V Á O 2max in lean control participants. Protein levels of oxidative phosphorylation complexes (I-V) were similar between patients with type 2 diabetes and obese control participants, but markedly increased in lean control participants compared with the other groups ( Table 2) . Indicative of a decreased antioxidant capacity in patients with type 2 diabetes, MnSOD was lower than in lean control participants (p<0.05), with a tendency towards higher MnSOD in obese controls than in patients with type 2 diabetes (p=0.057; Fig. 3e ). Inhibition of complex I with rotenone (Protocol-1) and of complex I and II with rotenone and malonic acid (Protocol-2) always resulted in a return of respiratory rates to baseline levels, providing additional evidence of the functionality of the experimental set-up (Fig. 3a, c) . When mitochondrial flux rates were expressed relative to mito- (Fig. 3b, d , f) and mtDNA (data not shown), no differences between the groups were seen. The most striking observation, however, was that mitochondrial substrate sensitivity was much higher (p<0.05) in patients with type 2 diabetes than in lean and obese controls when glutamate was used as substrate (Protocol-1; Fig. 4b, Table 3 ). A higher sensitivity was seen in patients with type 2 diabetes than in obese control participants when succinate was used as substrate (Protocol-2; Fig. 5b , Table 3 ). No difference was observed in sensitivity when octanoyl-carnitine (Protocol-3; Table 3 ) was used as substrate. V Á max was similar between patients with type 2 diabetes and obese control participants, but always higher (p<0.05) in lean control participants, except for under glutamate stimulation, where the difference was only significant compared with obese control participants ( Fig. 1a-e) .
In addition to the measurements in permeabilised fibres, substrate sensitivity was also determined in isolated mitochondria from a subset of the lean control group (n=4). C 50 was significantly higher in isolated mitochondria than in permeabilised fibres, both when testing complex I (glutamate) and complex II (succinate; ESM Fig. 2) .
Discussion
Main findings A major and novel finding of our study is that muscle mitochondrial substrate sensitivity was different between the experimental groups (Figs. 4b, 5b, Table 3 ). Patients with type 2 diabetes had a higher sensitivity than obese control participants when glutamate and succinate were used as substrates. Patients with type 2 diabetes also had a higher sensitivity than lean control participants, but only when glutamate was used as substrate. No differences were seen in mitochondrial substrate sensitivity between the three groups with octanoyl-carnitine as substrate. Substrate sensitivity was similar between obese and lean control participants with any substrate. At the same time maximal mitochondrial respiratory capacity per mitochondrion did not differ (Fig. 3b, d, f) . The type 2 diabetic patients and control participants were clearly distinct in insulin sensitivity (Fig. 2) , while antioxidant levels (MnSOD) and the proportion of the MHC I isoform were markedly lower in patients with type 2 diabetes.
Mitochondrial respiratory capacity The maximal coupled mitochondrial respiration per mg tissue normalised to mitochondrial content (citrate synthase activity or mtDNA) did not differ between the groups, who, in turn, had markedly different insulin sensitivity as determined by the clamp technique. Patients with type 2 diabetes and obese controls were very well matched. Moreover, even if the comparison of mitochondrial respiration (with or without correction for citrate synthase activity or mtDNA content) and insulin sensitivity is restricted to these two groups, it is evident that there is no positive relationship between mitochondrial respiration and insulin sensitivity. If the most insulin-sensitive group is brought into the comparison, i.e. the lean control group, it is also evident that per mitochondrion there is no difference in mitochondrial respiration between the three groups (type 2 diabetes, obese and lean controls). Naturally, there is a difference per amount of muscle in mitochondrial respiration in the permeabilised fibres, because the lean controls had a higher mitochondrial density, in line with a previous study in similar controls [8] . When maximal mitochondrial respiration is normalised to mitochondrial content (by citrate synthase activity), the findings in the present study are consistent with most [7] [8] [9] [24] [25] [26] but not all studies [3] using permeabilised fibres. Furthermore, calculation of respiratory and substrate control ratios showed similar results between groups. These ratios are independent of mitochondrial content (ESM Fig. 1a-e) .
The amount of mitochondria was not directly counted, but both citrate synthase and HAD activity, and mtDNA, were similar between patients with type 2 diabetes and obese controls, and were higher in lean controls, reflecting the higher level of fitness. These data are supported by measurements of protein content of the five complexes in the respiratory chain, which showed up to more than twofold higher values in lean controls than in patients with type 2 diabetes and in obese controls ( Table 2 ). The indices of mitochondrial density thus reflected the fact that the lean controls had a higher V Á O 2max than the other groups.
Mitochondrial substrate sensitivity While mitochondrial respiratory capacity did not differ between groups, data on substrate sensitivity did show differences. An increased sensitivity in mitochondrial respiratory kinetics in patients with type 2 diabetes compared with obese controls was seen when glutamate and succinate were used as substrates. The increased substrate sensitivity in patients with type 2 diabetes was confined to non-lipid substrates. The lower C 50 value found in patients with type 2 diabetes means that, for the same concentration of substrate in question, patients are closer to maximal mitochondrial respiratory capacity, i.e. they are more sensitive. The lower C 50 value (i.e. the higher sensitivity) was not due to differences in V Á max , since no differences were seen in V Á max between patients with type 2 diabetes and obese controls with any of the substrates. Mitochondrial substrate sensitivity was never different between lean and obese controls, while V Á max was different for all the substrates and whole-body V Á O 2max was also different between lean and obese controls. Thus, neither V Á max nor V Á O 2max is related to mitochondrial substrate sensitivity. Finally, the comparison between the two control groups shows that obesity and physical fitness are not regulating factors in substrate sensitivity for complexes I or II. It is clear that patients with type 2 diabetes differ in substrate sensitivity for complexes I and II compared with obese controls, but not when compared with lean controls, who only differed from patients with type 2 diabetes in complex I. Thus a functional change of complex I in patients with type 2 diabetes is evident. For complex II, a change in function may also be evident in the patients with type 2 diabetes, but a firm conclusion cannot be made because C 50 for complex II was only lower than in obese and not in lean controls. The distinction may seem trivial, but further exploration of complex II sensitivity is appropriate.
The finding of a higher sensitivity in patients with type 2 diabetes is in contrast to our initial hypothesis. We had expected that the maximal respiratory capacity per mitochondrion would be similar (shown in the present and in other previous studies), but also that the diabetic muscle would be less sensitive to substrate handling, in line with the insulin resistance concept where diabetic muscle is less sensitive to the action of insulin. The data in the present study clearly underline the need to separate the molecular events of insulin resistance from the subsequent handling of those substrates available.
Several scenarios could verify the appropriateness of an increased complex I sensitivity in patients with type 2 diabetes. First, the increased mitochondrial substrate sensitivity in patients with type 2 diabetes compared with obese controls could be an adaptive mechanism in the muscle in order to compensate for a decreased glucose flux into the cell, i.e. compensation for insulin resistance. The fact that the adaptation is confined to non-lipid substrates (C 50 for the medium-chain fatty acid octanoyl-carnitine did not differ between groups) seems appropriate, as intracellular fatty acid availability is not in deficit in patients with type 2 diabetes [27] . Second, patients with type 2 diabetes had higher MHC II content (Table 2) , which in rats has been shown to have an increased substrate sensitivity (i.e. lower C 50 value) than type I fibres [16] . Differences in maximal mitochondrial respiration are seen between fibre types in rats [15] , but with mixed muscle fibres in humans, V Á max in patients with type 2 diabetes and obese controls (Table 3) would be expected to be similar. Third, the increased substrate sensitivity found in patients with type 2 diabetes may serve as a regulator for ROS production, because a high mitochondrial respiratory flux rate will decrease mitochondrial membrane potential, which in turn will lead to a decrease in ROS production [28] [29] [30] . The faster the cells increase their flux rate (i.e. the more substrate-sensitive they are), the less ROS is produced. Thus a higher complex I sensitivity would be an advantage, if ROS production should need to be minimised. Moreover, the higher proportion of type II fibres found in patients with type 2 diabetes may contribute to higher ROS production [10, 31] because type II fibres, at least in rat muscle [17] , produce more ROS. This is supported by the lower antioxidant defence system in our patients with type 2 diabetes than in the other groups (Table 2) . Protection from ROS can be evoked by decreasing the production of ROS or by increased antioxidant capacity, but the latter was clearly not the case in the present study (Table 2) , which is consistent with other studies [4, 6] . Further experiments are needed to provide final proof of these suggestions.
It has been suggested that metformin treatment has an inhibitory effect on complex I in the electron transport chain [32, 33] . However, this inhibition was found only at concentrations above 10 mmol/l. In humans, the plasma concentration does not exceed 0.03 mmol/l (4 μg/ml). Even if metformin were to accumulate in the mitochondrial matrix by a factor 1000, as proposed in other studies [32, 33] , the concentration would still be too low. Moreover, metformin has a relatively short half-life (approximate 6.5 h), which has not been taken into consideration above. These considerations fit well with our observation in the present study that patients with type 2 diabetes had similar substrate sensitivity in the metformin-treated and nonmetformin-treated subgroups. They also always had higher substrate sensitivity than obese controls. Thus, physiologically, metformin treatment does not seem to play any role in mitochondrial function in human skeletal muscle.
Our additional experiment with substrate sensitivity in isolated mitochondria revealed a two-to fourfold higher sensitivity for glutamate and succinate in permeabilised fibres than in isolated mitochondria. With the higher (and not lower) sensitivity in permeabilised muscle, we have therefore provided a proof-of-concept for phenomenon, as well as providing additional arguments for using permeabilised fibres for ex vivo studies of mitochondrial respiration. The lower substrate sensitivity in isolated mitochondria is probably due to the need for an intact cytoskeleton for full effect; this intactness is destroyed in the isolation procedure [34] .
Conclusion In summary, we have shown that skeletal muscle mitochondrial sensitivity for substrates for complexes I and II is markedly higher in patients with type 2 diabetes than in obese controls with normal glucose tolerance. We propose that this is an adaptive response, which serves to regulate ROS production in the face of impaired antioxidant capacity and a slightly higher content of MHC II isoforms in the muscle. We have also reconfirmed that mitochondrial respiratory capacity per mitochondrion is not linked to insulin resistance or type 2 diabetes. Finally, we have shown that obesity and physical fitness are not regulating factors in substrate sensitivity for complexes I or II.
